INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,055,798 | -23.1% | 596,195 | -6.5% | 0.02% | -4.8% |
| Q2 2023 | $40,369,033 | +11.7% | 637,540 | -4.4% | 0.02% | +5.0% |
| Q1 2023 | $36,125,577 | +12.4% | 667,139 | +9.8% | 0.02% | +5.3% |
| Q4 2022 | $32,152,128 | +24.5% | 607,561 | +9.4% | 0.02% | +18.8% |
| Q3 2022 | $25,833,000 | -16.9% | 555,199 | +2.0% | 0.02% | -5.9% |
| Q2 2022 | $31,084,000 | -0.8% | 544,549 | +6.3% | 0.02% | +13.3% |
| Q1 2022 | $31,348,000 | +16.2% | 512,304 | -0.6% | 0.02% | +25.0% |
| Q4 2021 | $26,970,000 | +263.3% | 515,300 | +158.8% | 0.01% | +200.0% |
| Q3 2021 | $7,424,000 | +19.3% | 199,120 | +30.6% | 0.00% | +33.3% |
| Q2 2021 | $6,225,000 | +292.0% | 152,474 | +225.6% | 0.00% | +200.0% |
| Q1 2021 | $1,588,000 | -3.5% | 46,824 | -9.5% | 0.00% | 0.0% |
| Q4 2020 | $1,645,000 | +70.6% | 51,733 | +37.8% | 0.00% | 0.0% |
| Q3 2020 | $964,000 | +24.9% | 37,543 | +25.0% | 0.00% | 0.0% |
| Q2 2020 | $772,000 | -8.3% | 30,043 | -45.1% | 0.00% | 0.0% |
| Q1 2020 | $842,000 | +56.8% | 54,765 | +249.3% | 0.00% | – |
| Q4 2019 | $537,000 | -61.6% | 15,678 | -91.6% | 0.00% | -100.0% |
| Q3 2019 | $1,400,000 | -55.8% | 187,619 | -23.2% | 0.00% | -50.0% |
| Q2 2019 | $3,169,000 | +97.7% | 244,184 | +85.2% | 0.00% | +100.0% |
| Q1 2019 | $1,603,000 | -39.3% | 131,829 | -43.2% | 0.00% | -50.0% |
| Q4 2018 | $2,642,000 | -75.4% | 232,148 | -53.0% | 0.00% | -33.3% |
| Q3 2018 | $10,721,000 | -49.0% | 494,184 | -58.5% | 0.00% | -50.0% |
| Q2 2018 | $21,034,000 | +25.8% | 1,190,431 | +49.9% | 0.01% | -25.0% |
| Q1 2018 | $16,717,000 | +48.3% | 794,287 | +2.0% | 0.01% | +14.3% |
| Q4 2017 | $11,274,000 | +6.8% | 778,776 | +16.4% | 0.01% | 0.0% |
| Q3 2017 | $10,558,000 | +31.5% | 669,140 | +3.4% | 0.01% | +16.7% |
| Q2 2017 | $8,031,000 | +6.0% | 646,883 | +38.7% | 0.01% | 0.0% |
| Q1 2017 | $7,577,000 | +31.2% | 466,390 | +21.9% | 0.01% | +20.0% |
| Q4 2016 | $5,774,000 | +117.6% | 382,734 | +119.6% | 0.01% | +150.0% |
| Q3 2016 | $2,654,000 | +561.8% | 174,315 | +1576.3% | 0.00% | – |
| Q2 2016 | $401,000 | -75.0% | 10,399 | -82.0% | 0.00% | -100.0% |
| Q1 2016 | $1,605,000 | +114.6% | 57,768 | +314.7% | 0.00% | 0.0% |
| Q4 2015 | $748,000 | -83.0% | 13,930 | -87.3% | 0.00% | -66.7% |
| Q3 2015 | $4,392,000 | +2545.8% | 109,715 | +2004.2% | 0.00% | – |
| Q2 2015 | $166,000 | -23.1% | 5,214 | -42.7% | 0.00% | – |
| Q1 2015 | $216,000 | -15.3% | 9,093 | -37.4% | 0.00% | – |
| Q4 2014 | $255,000 | +8.5% | 14,531 | -15.6% | 0.00% | – |
| Q3 2014 | $235,000 | -57.3% | 17,223 | -47.3% | 0.00% | – |
| Q2 2014 | $550,000 | -39.4% | 32,667 | -34.7% | 0.00% | -100.0% |
| Q1 2014 | $908,000 | – | 50,002 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |